These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 33449393)

  • 1. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
    Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
    Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
    Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
    Sun SH; Benner B; Savardekar H; Lapurga G; Good L; Abood D; Nagle E; Duggan M; Stiff A; DiVincenzo MJ; Suarez-Kelly LP; Campbell A; Yu L; Wesolowski R; Howard H; Shah H; Kendra K; Carson WE
    Front Immunol; 2021; 12():740890. PubMed ID: 34712230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
    Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
    Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
    Front Immunol; 2020; 11():372. PubMed ID: 32210968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
    Saito R; Sawada Y; Nakamura M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood.
    Rad Pour S; Pico de Coaña Y; Demorentin XM; Melief J; Thimma M; Wolodarski M; Gomez-Cabrero D; Hansson J; Kiessling R; Tegner J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. uPAR
    Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
    Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
    Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients.
    Petrova V; Groth C; Bitsch R; Arkhypov I; Simon SCS; Hetjens S; Müller V; Utikal J; Umansky V
    Front Immunol; 2023; 14():1065767. PubMed ID: 36860876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors.
    Grigoriou M; Banos A; Hatzioannou A; Kloetgen A; Kouzis P; Aggouraki D; Zakopoulou R; Bamias G; Kassi E; Mavroudis D; Bamias A; Boumpas DT; Tsirigos A; Gogas H; Alissafi T; Verginis P
    Cancer Immunol Res; 2021 Jul; 9(7):726-734. PubMed ID: 33820810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early versus late response to PD-1-based immunotherapy in metastatic melanoma.
    Lodde GC; Zhao F; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Jansen P; Kowall B; Galetzka W; Hörst F; Kleesiek J; Hellwig B; Rahnenführer J; Rajcsanyi L; Peters T; Hinney A; Placke JM; Sucker A; Paschen A; Becker JC; Livingstone E; Zimmer L; Tasdogan A; Roesch A; Hadaschik E; Schadendorf D; Griewank K; Ugurel S
    Eur J Cancer; 2024 Oct; 210():114295. PubMed ID: 39213786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
    Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
    Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis.
    Möller M; Orth V; Umansky V; Hetjens S; Braun V; Reißfelder C; Hardt J; Seyfried S
    Front Immunol; 2024; 15():1403771. PubMed ID: 38855104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.
    Hernandez C; Arasanz H; Chocarro L; Bocanegra A; Zuazo M; Fernandez-Hinojal G; Blanco E; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
    Versluis JM; Hendriks AM; Weppler AM; Brown LJ; de Joode K; Suijkerbuijk KPM; Zimmer L; Kapiteijn EW; Allayous C; Johnson DB; Hepner A; Mangana J; Bhave P; Jansen YJL; Trojaniello C; Atkinson V; Storey L; Lorigan P; Ascierto PA; Neyns B; Haydon A; Menzies AM; Long GV; Lebbe C; van der Veldt AAM; Carlino MS; Sandhu S; van Tinteren H; de Vries EGE; Blank CU; Jalving M
    Eur J Cancer; 2021 Jul; 151():72-83. PubMed ID: 33971447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma.
    Kött J; Zimmermann N; Zell T; Heidrich I; Geidel G; Rünger A; Smit DJ; Merkle M; Parnian N; Hansen I; Hoehne I; Abeck F; Torster L; Weichenthal M; Pantel K; Schneider SW; Gebhardt C
    J Eur Acad Dermatol Venereol; 2024 Aug; 38(8):1575-1587. PubMed ID: 38466133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma.
    Nardin C; Laheurte C; Puzenat E; Boullerot L; Ramseyer M; Marguier A; Jacquin M; Godet Y; Aubin F; Adotevi O
    J Invest Dermatol; 2022 Feb; 142(2):435-444. PubMed ID: 34352265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
    Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
    J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study.
    Liu R; Yang F; Yin JY; Liu YZ; Zhang W; Zhou HH
    Front Immunol; 2021; 12():685370. PubMed ID: 34220837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.